Quick search

For manufacturers

Our company

Follow us on social media

Login to your account

email
{{ errors.first('email') }}
lock
{{ errors.first('password') }}
Log In

Don’t have an account?

Join
News & views
keyboard_arrow_left back

News & views

Announcements, editorials, and insights from the global orthopaedic and spine industry

today Published on 07-01-2019

Sintx Announces 30-Year Spine Fusion Data With Silicon Nitride Implants

Sintx Announces 30-Year Spine Fusion Data With Silicon Nitride Implants

SALT LAKE CITY, Jan. 03, 2019 (GLOBE NEWSWIRE) -- SINTX Technologies (NASDAQ: SINT) today reported the independent publication of 30-year clinical outcomes of lumbar fusion surgeries, performed with silicon nitride implants. The paper titled “Anterior Lumbar Interbody Fusion Using Reaction Bonded Silicon Nitride Implants” appeared in the December 2018 edition of the World Neurosurgery journal, and the findings were also featured at the 2018 Annual Scientific Meeting of the Neurosurgical Society of Australasia.

Dr. Ralph Mobbs from the University of New South Wales, Sydney, authored the study. Dr. Mobbs stated: “This work is of historical significance, being the first clinical study of silicon nitride as an implant material, the first commercial anterior lumbar interbody fusion with a synthetic material, the first design of a spinal interbody implant with endplate porosity to promote fusion, and the longest clinical follow-up of any implant material in spine surgery. This report clearly establishes the place of silicon nitride in the annals of spine surgery,” said Professor Mobbs.

“This work reflects the only known use of silicon nitride implants, outside the spine products manufactured by our company,” said Dr. Sonny Bal, Chairman of SINTX Technologies. “Despite a much earlier material composition and implant design, silicon nitride proved itself even three decades after spinal implantation. These findings are entirely consistent with the more modern data published by us, showing earlier fusion, excellent biocompatibility, ease of radiographic imaging, and other advantages of our silicon nitride spine implants. The SINTX formulation of silicon nitride is enhanced and improved even further with sintering agents that accelerate bioactivity and confer antibacterial advantages.”

“This paper is a compelling affirmation of our full confidence in silicon nitride as the ideal spine biomaterial platform, whether as an implant, surface coating, or composite formulation with other biomaterials. This report will support our sales objectives, as we prepare an official launch in the coming months in Australia - the first place to use silicon nitride in spinal fusion surgery,” said Daniel Chon, CEO of Dallas-based CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants made by SINTX Technologies.

About SINTX Technologies

SINTX Technologies is an innovative biomaterials and OEM company that develops and commercializes silicon nitride for various biomedical applications including orthopedic, dental and arthroplasty.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. A discussion of those risks and uncertainties can be found in Sintx's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2018, and in Sintx's other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. Sintx undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Contacts:
SINTX Technologies
801-839-3502
IR@sintx.com

SOURCE: GlobeNewswire January 03,2019